NRXP — NRX Pharmaceuticals Balance Sheet
0.000.00%
- $73.41m
- $65.61m
- $1.23m
Annual balance sheet for NRX Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 27.6 | 20.1 | 4.59 | 1.44 | 7.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 0.161 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32.7 | 25.8 | 6.88 | 3.3 | 8.89 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | — | 0.01 | 0.696 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 32.7 | 25.8 | 7.32 | 3.65 | 13 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.9 | 15.6 | 19 | 21.9 | 28.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.9 | 18.4 | 19 | 26.9 | 28.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 20.8 | 7.41 | -11.7 | -23.2 | -15.9 |
| Total Liabilities & Shareholders' Equity | 32.7 | 25.8 | 7.32 | 3.65 | 13 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |